Cargando…
Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
BACKGROUND: We aimed to detect SARS-CoV-2 serum antibodies in the general population of the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic wave. METHODS: Participants (n=3207, aged 2–90 years), enrolled from a previously established nationwide serosurveil...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142429/ https://www.ncbi.nlm.nih.gov/pubmed/33249407 http://dx.doi.org/10.1136/jech-2020-215678 |
_version_ | 1783696549247713280 |
---|---|
author | Vos, Eric R A den Hartog, Gerco Schepp, Rutger M Kaaijk, Patricia van Vliet, Jeffrey Helm, Kina Smits, Gaby Wijmenga-Monsuur, Alienke Verberk, Janneke D M van Boven, Michiel van Binnendijk, Rob S de Melker, Hester E Mollema, Liesbeth van der Klis, Fiona R M |
author_facet | Vos, Eric R A den Hartog, Gerco Schepp, Rutger M Kaaijk, Patricia van Vliet, Jeffrey Helm, Kina Smits, Gaby Wijmenga-Monsuur, Alienke Verberk, Janneke D M van Boven, Michiel van Binnendijk, Rob S de Melker, Hester E Mollema, Liesbeth van der Klis, Fiona R M |
author_sort | Vos, Eric R A |
collection | PubMed |
description | BACKGROUND: We aimed to detect SARS-CoV-2 serum antibodies in the general population of the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic wave. METHODS: Participants (n=3207, aged 2–90 years), enrolled from a previously established nationwide serosurveillance study, provided a self-collected fingerstick blood sample and completed a questionnaire (median inclusion date 3 April 2020). IgG antibodies targeted against the spike S1-protein of SARS-CoV-2 were quantified using a validated multiplex-immunoassay. Seroprevalence was estimated controlling for survey design, individual pre-pandemic concentration, and test performance. Random-effects logistic regression identified risk factors for seropositivity. RESULTS: Overall seroprevalence in the Netherlands was 2.8% (95% CI 2.1 to 3.7), with no differences between sexes or ethnic background, and regionally ranging between 1.3 and 4.0%. Estimates were highest among 18–39 year-olds (4.9%), and lowest in children 2–17 years (1.7%). Multivariable analysis revealed that persons taking immunosuppressants and those from the Orthodox-Reformed Protestant community had over four times higher odds of being seropositive compared to others. Anosmia/ageusia was the most discriminative symptom between seropositive (53%) and seronegative persons (4%, p<0.0001). Antibody concentrations in seropositive persons were significantly higher in those with fever or dyspnoea in contrast to those without (p=0.01 and p=0.04, respectively). CONCLUSIONS: In the midst of the first epidemic wave, 2.8% of the Dutch population was estimated to be infected with SARS-CoV-2, that is, 30 times higher than reported. This study identified independent groups with increased odds for seropositivity that may require specific surveillance measures to guide future protective interventions internationally, including vaccination once available. |
format | Online Article Text |
id | pubmed-8142429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-81424292021-06-07 Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave Vos, Eric R A den Hartog, Gerco Schepp, Rutger M Kaaijk, Patricia van Vliet, Jeffrey Helm, Kina Smits, Gaby Wijmenga-Monsuur, Alienke Verberk, Janneke D M van Boven, Michiel van Binnendijk, Rob S de Melker, Hester E Mollema, Liesbeth van der Klis, Fiona R M J Epidemiol Community Health Original Research BACKGROUND: We aimed to detect SARS-CoV-2 serum antibodies in the general population of the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic wave. METHODS: Participants (n=3207, aged 2–90 years), enrolled from a previously established nationwide serosurveillance study, provided a self-collected fingerstick blood sample and completed a questionnaire (median inclusion date 3 April 2020). IgG antibodies targeted against the spike S1-protein of SARS-CoV-2 were quantified using a validated multiplex-immunoassay. Seroprevalence was estimated controlling for survey design, individual pre-pandemic concentration, and test performance. Random-effects logistic regression identified risk factors for seropositivity. RESULTS: Overall seroprevalence in the Netherlands was 2.8% (95% CI 2.1 to 3.7), with no differences between sexes or ethnic background, and regionally ranging between 1.3 and 4.0%. Estimates were highest among 18–39 year-olds (4.9%), and lowest in children 2–17 years (1.7%). Multivariable analysis revealed that persons taking immunosuppressants and those from the Orthodox-Reformed Protestant community had over four times higher odds of being seropositive compared to others. Anosmia/ageusia was the most discriminative symptom between seropositive (53%) and seronegative persons (4%, p<0.0001). Antibody concentrations in seropositive persons were significantly higher in those with fever or dyspnoea in contrast to those without (p=0.01 and p=0.04, respectively). CONCLUSIONS: In the midst of the first epidemic wave, 2.8% of the Dutch population was estimated to be infected with SARS-CoV-2, that is, 30 times higher than reported. This study identified independent groups with increased odds for seropositivity that may require specific surveillance measures to guide future protective interventions internationally, including vaccination once available. BMJ Publishing Group 2021-06 2020-11-30 /pmc/articles/PMC8142429/ /pubmed/33249407 http://dx.doi.org/10.1136/jech-2020-215678 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Vos, Eric R A den Hartog, Gerco Schepp, Rutger M Kaaijk, Patricia van Vliet, Jeffrey Helm, Kina Smits, Gaby Wijmenga-Monsuur, Alienke Verberk, Janneke D M van Boven, Michiel van Binnendijk, Rob S de Melker, Hester E Mollema, Liesbeth van der Klis, Fiona R M Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave |
title | Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave |
title_full | Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave |
title_fullStr | Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave |
title_full_unstemmed | Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave |
title_short | Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave |
title_sort | nationwide seroprevalence of sars-cov-2 and identification of risk factors in the general population of the netherlands during the first epidemic wave |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142429/ https://www.ncbi.nlm.nih.gov/pubmed/33249407 http://dx.doi.org/10.1136/jech-2020-215678 |
work_keys_str_mv | AT vosericra nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT denhartoggerco nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT schepprutgerm nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT kaaijkpatricia nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT vanvlietjeffrey nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT helmkina nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT smitsgaby nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT wijmengamonsuuralienke nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT verberkjannekedm nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT vanbovenmichiel nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT vanbinnendijkrobs nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT demelkerhestere nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT mollemaliesbeth nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave AT vanderklisfionarm nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave |